Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...

Beam Therapeutics BEAM and Intellia Therapeutics NTLA are clinical-stage companies developing investigational gene therapies.

Eli Lilly’s LLY recent announcement to acquire Verve Therapeutics, Inc VERV, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, has put the spotlight on ...

Shares of gene editing companies were largely steady in the premarket on Friday after the FDA’s Center for Biologics Research and Evaluation (CBER) faced another abrupt leadership transition following ...

On Tuesday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Verve Therapeutics, Inc. (NASDAQ:VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. Lilly ...

Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine ...

Regeneron Pharmaceuticals, Inc. REGN announced a collaboration agreement with private company Tessera Therapeutics, Inc. for ...

Explore Precision BioSciences' advances in gene therapy for hepatitis B, strong funding till 2028, and what it means for ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, Canaccord Genuity analyst John Newman reaffirmed a Buy rating on ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to ...

Revolutions in gene therapy are rapidly changing the landscape of modern medicine, forcing society and science alike to ...